

Applicants: Sawyers et al.  
U.S. Serial No.: 10/066,266  
Filed: January 30, 2002  
Page: 4

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. If, however, a fee is deemed necessary, Applicants hereby authorize the Patent Office to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano  
Registration No. 34,470  
Stephanie Hsieh  
Registration No. 38,497  
Attorneys for Applicants  
MANDEL & ADRIANO  
35 N Arroyo Parkway  
Pasadena, California 91103  
(626) 395-7801  
Customer No. 26, 941

Applicants: Sawyers et al.  
U.S. Serial No.: 10/066,266  
Filed: January 30, 2002  
Page: 5

**EXHIBIT 1**

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the claims:**

Please cancel claim 1, without prejudice. Please add new claims 2-10 as follows:

- 2. (New) A method for determining whether a gene of interest has an effect on the progression of human prostate cancer, comprising:
- a. introducing the gene to an immune deficient subject mouse comprising a human prostate cancer xenograft of locally advanced or metastatic prostate cancer issue or a cell suspension thereof;
  - b. transducing cells of the xenograft with the gene *in vivo* in the subject mouse;
  - c. providing a control immune deficient mouse comprising the xenograft, wherein cells of the xenograft in the control mouse are not transduced;
  - d. identifying the presence of micrometastasis or macrometastasis in the subject mouse by detecting prostate cancer cells in the peripheral blood, bone marrow, bone, lymph nodes or a site distant from the xenograft;
  - e. identifying the presence of micrometastasis or macrometastasis in the control mouse by detecting prostate cancer cells in the peripheral blood, bone marrow, bone, lymph nodes or a site distant from the xenograft; and,

Applicants: Sawyers et al.  
 U.S. Serial No.: 10/066,266  
 Filed: January 30, 2002  
 Page: 6

- f. evaluating the effect of the gene on the progression of prostate cancer by comparing cancer progression in the subject mouse to cancer progression in the control mouse.--
- 3. (New) The method of claim 2, wherein the introducing step introduces the gene to an immune deficient subject mouse bearing a subcutaneous xenograft.--
- 4. (New) The method of claim 2, wherein the introducing step introduces the gene to an immune deficient subject mouse bearing an intraprostatic human prostate xenograft.--
- 5. (New) The method of claim 2, wherein the introducing step introduces the gene to an immune deficient subject mouse bearing an intrabone human prostate cancer xenograft.--
- 6. (New) A method for identifying a gene that minimizes progression of human prostate cancer, comprising the method of claim 2, and further comprising a step of:
  - g. selecting a gene that impairs the progression of prostate cancer in the subject mouse relative to cancer progression in the control mouse.--
- 7. (New) A method for identifying a gene that facilitates progression of human prostate cancer, comprising the method of claim 2, further comprising a step of:
  - g. selecting a gene that facilitates progression of prostate cancer in the subject mouse relative to cancer progression in the control mouse.--
- 8. (New) A gene whose function has been identified by a process of claim 6.--

Applicants: Sawyers et al.  
U.S. Serial No.: 10/066,266  
Filed: January 30, 2002  
Page: 7

- 9. (New) A gene whose function has been identified by a process of claim 7.--
- 10. (New) A method for impairing the progression of human prostate cancer comprising transducing human prostate cancer cells *in vivo* with the gene of claim 8.--